Nurix Therapeutics Cash Flow Statement
NASDAQ: NRIXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
22.35+0.14 (+0.63%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Nurix Therapeutics free cash flow
In fiscal 2025, Nurix Therapeutics generated -$249.5 million of operating cash flow and spent $14.0 million on capital expenditures. That left free cash flow of -$263.5 million, a free-cash-flow margin of -313.7% of revenue.
Summary generated from market data by MetaCap's automated system. Methodology
Nurix Therapeutics cash flow statement (annual)
| Fiscal year (USD) | FY 20252025-11-30 | FY 20242024-11-30 | FY 20232023-11-30 | FY 20222022-11-30 | FY 20212021-11-30 | FY 20202020-11-30 | FY 20192019-11-30 |
|---|---|---|---|---|---|---|---|
| Net Income | -264.46M | -193.57M | -143.95M | -180.36M | -117.19M | -43.24M | -21.70M |
| Net Income growth (YoY) | — | — | — | — | — | — | — |
| Depreciation & Amortization | 8.74M | 9.32M | 7.53M | 5.35M | 2.79M | 2.18M | 2.35M |
| Stock-Based Compensation | 37.97M | 33.93M | 33.67M | 28.13M | 15.80M | 4.30M | 510.00K |
| Change in Working Capital | -43.84M | -23.80M | 23.27M | -21.64M | 4.40M | 45.47M | 17.17M |
| Operating Cash Flow | -249.47M | -172.58M | -81.36M | -159.81M | -84.36M | -80.00K | 601.00K |
| Capital Expenditures | -14.00M | -9.27M | -8.40M | -12.24M | -5.66M | -4.55M | -1.65M |
| Investing Cash Flow | 147.85M | -257.71M | 68.30M | 27.20M | -108.25M | -254.40M | 8.50M |
| Financing Cash Flow | 238.64M | 485.67M | 3.22M | 117.19M | 153.88M | 339.02M | 126.00K |
| Net Change in Cash | 137.03M | 55.37M | -9.85M | -15.42M | -38.73M | 84.54M | 9.22M |
| Free Cash Flow | -263.47M | -181.86M | -89.77M | -172.05M | -90.03M | -4.63M | -1.05M |
This table shows 7 annual periods of Nurix Therapeutics's cash flow statement, from FY 2025 back to FY 2019, across 10 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow NRIX's reporting calendar. What is a cash flow statement?